Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Int Immunol. 2011 Jun;23(6):391-403. doi: 10.1093/intimm/dxr028. Epub 2011 May 19.
The erbb-2 gene receptor is often over-expressed in human cancer and its overexpression is accompanied by worse prognosis. Targeting erbb-2 gene with antibodies is an effective approach to curtail the progression of erbb-2 gene-expressing cancer types. Two monoclonal antibodies, L-26 and N-12, previously generated in our laboratory, have shown effective tumor inhibition in mice, especially when used in combination. Here, we describe novel peptide mimics of erbb-2 gene protein epitopes, also called mimotopes, that were selected from a constraint random 12-mer peptide phage library, specific for the antibodies L-26 and N-12. Initial sequencing analyses revealed little sequence conservation among the peptide mimotopes, and no sequence homology with the erbb-2 gene protein. However, computational analyses of the two groups of peptides, specific for L-26 and N-12, suggested different epitopes on the erbb-2 gene extracellular domain. In vitro assays showed that the phage displayed peptide mimotopes were specific to their respective antibodies. Selected cyclic peptide mimotopes, but not their corresponding linear equivalents, were able to inhibit binding of the antibodies L-26 and N-12 to the surface of erbb-2 gene-expressing cancer cells in a concentration-dependent manner. In line with this observation, phage-displayed cyclic peptides successfully competed in vitro with recombinant erbb-2 gene protein for binding to their respective antibodies L-26 or N-12. Consistent with the antibody inhibition experiments, we detected specific anti-erbb-2 gene antibodies following vaccination with KLH-coupled cyclic peptides but not with multiple antigenic linear peptides. Potentially, the selected peptides could serve as a starting point for the development of a vaccine against erbb-2 gene over-expressing cancer.
erbB-2 基因受体在人类癌症中经常过表达,其过表达伴随着更差的预后。用抗体靶向 erbB-2 基因是一种有效抑制 erbB-2 基因表达型癌症进展的方法。我们实验室之前生成的两种单克隆抗体 L-26 和 N-12 在小鼠中显示出有效的肿瘤抑制作用,尤其是联合使用时。在这里,我们描述了从针对抗体 L-26 和 N-12 的约束随机 12 肽噬菌体文库中选择的 erbB-2 基因蛋白表位的新型肽模拟物,也称为模拟表位。初始测序分析显示肽模拟物之间序列一致性很小,与 erbB-2 基因蛋白没有序列同源性。然而,针对 L-26 和 N-12 的两组肽的计算分析表明,erbB-2 基因细胞外结构域上存在不同的表位。体外试验表明,噬菌体展示的肽模拟物特异性针对其各自的抗体。所选环状肽模拟物,但不是其相应的线性等价物,能够以浓度依赖的方式抑制抗体 L-26 和 N-12 与 erbB-2 基因表达癌细胞表面的结合。与这一观察结果一致,噬菌体展示的环状肽成功地与重组 erbB-2 基因蛋白在体外竞争结合其各自的抗体 L-26 或 N-12。与抗体抑制实验一致,我们在用 KLH 偶联的环状肽接种后检测到针对 erbB-2 基因的特异性抗体,但用多种抗原线性肽则没有。潜在地,所选的肽可以作为开发针对 erbB-2 基因过表达癌症的疫苗的起点。